The role of anti-inflammatory medication, and thereby the reduction of CRP, in reducing cancer risk has been suggested in colon cancer, with a statistically significant difference in CRP seen between the absence and presence of colon cancer (Baron et al. 2003; Erlinger et al. 2004). Here, CRP is linked to malignant colon neoplasm.